Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) Taking Salmeterol Xinafoate/Fluticasone Propionate Combination
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Once-Daily Orally Administered PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) On A Background Of Salmeterol Xinafoate/ Fluticasone Propionate Combination
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Buenos Aires, Argentina, 1426
- Pfizer Investigational Site
-
-
Buenos Aires
-
Capital Federal, Buenos Aires, Argentina, C1440BRR
- Pfizer Investigational Site
-
-
Santa Fe
-
Rosario, Santa Fe, Argentina, 2000
- Pfizer Investigational Site
-
-
-
-
South Australia
-
Daw Park, South Australia, Australia, 5041
- Pfizer Investigational Site
-
-
Western Australia
-
Nedlands, Western Australia, Australia, 6009
- Pfizer Investigational Site
-
-
-
-
-
Ruse, Bulgaria, 7002
- Pfizer Investigational Site
-
Sevlievo, Bulgaria, 5400
- Pfizer Investigational Site
-
Sofia, Bulgaria, 1431
- Pfizer Investigational Site
-
Sofia, Bulgaria, 1407
- Pfizer Investigational Site
-
Stara Zagora, Bulgaria, 6003
- Pfizer Investigational Site
-
-
-
-
-
Quebec, Canada, G1V 4G5
- Pfizer Investigational Site
-
-
Alberta
-
Calgary, Alberta, Canada, T1Y 6J4
- Pfizer Investigational Site
-
-
Ontario
-
Niagara Falls, Ontario, Canada, L2G 1J4
- Pfizer Investigational Site
-
Ottawa, Ontario, Canada, K1Y 4G2
- Pfizer Investigational Site
-
Toronto, Ontario, Canada, M6H 3M2
- Pfizer Investigational Site
-
-
Quebec
-
Trois-Rivieres, Quebec, Canada, G8T 7A1
- Pfizer Investigational Site
-
-
-
-
V Region
-
Quillota, V Region, Chile, 2260494
- Pfizer Investigational Site
-
Valparaiso, V Region, Chile, 2352499
- Pfizer Investigational Site
-
-
-
-
-
Kutna Hora, Czech Republic, 284 01
- Pfizer Investigational Site
-
Liberec, Czech Republic, 460 01
- Pfizer Investigational Site
-
Pardubice, Czech Republic, 530 09
- Pfizer Investigational Site
-
Praha 10- Malesice, Czech Republic, 108 00
- Pfizer Investigational Site
-
Tabor, Czech Republic, 39001
- Pfizer Investigational Site
-
-
-
-
-
Budapest, Hungary, 1125
- Pfizer Investigational Site
-
Gyula, Hungary, 5703
- Pfizer Investigational Site
-
Szeged, Hungary, 6722
- Pfizer Investigational Site
-
Szombathely, Hungary, 9700
- Pfizer Investigational Site
-
-
-
-
Gujarat
-
Ahmedabad, Gujarat, India, 380 052
- Pfizer Investigational Site
-
-
Maharashtra
-
Nagpur, Maharashtra, India, 440 012
- Pfizer Investigational Site
-
-
Tamil Nadu
-
Coimbatore, Tamil Nadu, India, 641 004
- Pfizer Investigational Site
-
-
-
-
-
Newtown, New Zealand, 6021
- Pfizer Investigational Site
-
Tauranga, New Zealand, 3110
- Pfizer Investigational Site
-
-
-
-
-
Leczna, Poland, 21-010
- Pfizer Investigational Site
-
Warszawa, Poland, 04-141
- Pfizer Investigational Site
-
Zawadzkie, Poland, 47-120
- Pfizer Investigational Site
-
-
-
-
-
Bojnice, Slovakia, 972 01
- Pfizer Investigational Site
-
Bratislava, Slovakia, 826 06
- Pfizer Investigational Site
-
Kosice, Slovakia, 040 01
- Pfizer Investigational Site
-
Liptovsky Hradok, Slovakia, 033 01
- Pfizer Investigational Site
-
Povazska Bystrica, Slovakia, 017 26
- Pfizer Investigational Site
-
Spisska Nova Ves, Slovakia, 052 01
- Pfizer Investigational Site
-
-
-
-
-
Bloemfontein, South Africa, 9301
- Pfizer Investigational Site
-
-
Cape Town
-
Bellville, Cape Town, South Africa, 7530
- Pfizer Investigational Site
-
Tygerberg Campus, Cape Town, South Africa, 7505
- Pfizer Investigational Site
-
-
Durban
-
Amanzimtoti, Durban, South Africa, 4126
- Pfizer Investigational Site
-
-
Kwa-Zulu Natal
-
Durban, Kwa-Zulu Natal, South Africa, 4001
- Pfizer Investigational Site
-
-
-
-
-
Goteborg, Sweden, 413 45
- Pfizer Investigational Site
-
Goteborg, Sweden, 400 14
- Pfizer Investigational Site
-
Lund, Sweden, 22185
- Pfizer Investigational Site
-
Stockholm, Sweden, 171 76
- Pfizer Investigational Site
-
-
-
-
-
Glasgow, United Kingdom, G12 OYN
- Pfizer Investigational Site
-
-
Hull
-
Cottingham, Hull, United Kingdom, HU16 5JQ
- Pfizer Investigational Site
-
-
-
-
Alabama
-
Mobile, Alabama, United States, 36608
- Pfizer Investigational Site
-
-
Arizona
-
Glendale, Arizona, United States, 85306
- Pfizer Investigational Site
-
-
California
-
San Diego, California, United States, 92120
- Pfizer Investigational Site
-
-
Florida
-
Clearwater, Florida, United States, 33756
- Pfizer Investigational Site
-
Pensacola, Florida, United States, 32504
- Pfizer Investigational Site
-
Tampa, Florida, United States, 33603
- Pfizer Investigational Site
-
Tampa, Florida, United States, 33613
- Pfizer Investigational Site
-
Trinity, Florida, United States, 34655
- Pfizer Investigational Site
-
-
Georgia
-
Conyers, Georgia, United States, 30094
- Pfizer Investigational Site
-
Duluth, Georgia, United States, 30096
- Pfizer Investigational Site
-
Norcross, Georgia, United States, 30071
- Pfizer Investigational Site
-
-
Michigan
-
Livonia, Michigan, United States, 48152
- Pfizer Investigational Site
-
-
Minnesota
-
Fridley, Minnesota, United States, 55432
- Pfizer Investigational Site
-
Minneapolis, Minnesota, United States, 55407
- Pfizer Investigational Site
-
Rochester, Minnesota, United States, 55905
- Pfizer Investigational Site
-
-
Missouri
-
St. Louis, Missouri, United States, 63141
- Pfizer Investigational Site
-
-
Ohio
-
Cincinnati, Ohio, United States, 45231
- Pfizer Investigational Site
-
Cincinnati, Ohio, United States, 45245
- Pfizer Investigational Site
-
-
Rhode Island
-
Lincoln, Rhode Island, United States, 02865
- Pfizer Investigational Site
-
-
South Carolina
-
Spartanburg, South Carolina, United States, 29303
- Pfizer Investigational Site
-
-
Texas
-
Houston, Texas, United States, 77030
- Pfizer Investigational Site
-
Mckinney, Texas, United States, 75069
- Pfizer Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female subjects between, and including, the ages of 40 and 80 years.
- Subjects with a diagnosis, for at least 6 months, of moderate to severe COPD (GOLD) and who meet the criteria for Stage II-III disease.
- Subjects must have a smoking history of at least 10 pack-years and be current smokers or ex-smokers that gave up > 6 months ago.
- Subjects must be treated with a LABA/ICS combination for at least 1 month prior to screening.
Exclusion Criteria:
- A COPD exacerbation requiring treatment with oral steroids or hospitalization for the treatment of COPD within 3 months of screening.
- History or presence of significant cardiovascular disease.
- ECG abnormalities.
- Significant concomitant clinical disease that could interfere with the conduct, safety or interpretation of results of this study.
- Evidence of organ or blood disorders.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
Placebo oral tablet once daily for 12 weeks
|
|
Experimental: PH-797804
|
6 mg oral tablet once daily for 12 weeks
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Spirometry measures during 12 weeks of treatment and up to 2 weeks post treatment.
Time Frame: 12 Weeks
|
12 Weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Safety and tolerability measures (AEs, 12-lead ECG, lab safety) during 12 weeks of treatment and up to 2 weeks post treatment.
Time Frame: 12 Weeks
|
12 Weeks
|
|
Dyspnea index scores.
Time Frame: 12 Weeks
|
12 Weeks
|
|
Rescue bronchodilator usage.
Time Frame: 12 Weeks
|
12 Weeks
|
|
Symptom scores.
Time Frame: 12 Weeks
|
12 Weeks
|
|
Global impression of change (patient and clinician).
Time Frame: 12 Weeks
|
12 Weeks
|
|
Blood sample for pharmacokinetics.
Time Frame: 12 Weeks
|
12 Weeks
|
|
Blood and urine sample for biomarkers and molecular profiling.
Time Frame: 12 Weeks
|
12 Weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- A6631029
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.